Company Description
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system.
It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses.
The company is headquartered in Boston, Massachusetts.
| Country | United States |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 45 |
| CEO | Paula Ragan |
Contact Details
Address: 61 North Beacon Street, 4th Floor Boston, Massachusetts 02134 United States | |
| Phone | 857 529 8300 |
| Website | x4pharma.com |
Stock Details
| Ticker Symbol | XFOR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1501697 |
| CUSIP Number | 98420X202 |
| ISIN Number | US98420X2027 |
| Employer ID | 27-3181608 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Adam R. Craig M.B.A., M.D., Ph.D. | Executive Chair |
| John P. Volpone M.B.A. | President and Chief Operating Officer |
| David H. Kirske | Chief Financial Officer, Treasurer and Corporate Secretary |
| Dr. Richard Peters M.D., Ph.D. | Founder |
| Dr. Renato T. Skerlj Ph.D. | Founder |
| Dr. Keith T. Flaherty M.D. | Founder and Member of Corporate Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 20, 2026 | ARS | Filing |
| Mar 20, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 20, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 18, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 17, 2026 | 10-K | Annual Report |
| Mar 6, 2026 | SCHEDULE 13G/A | Filing |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 17, 2026 | SCHEDULE 13G | Filing |